Skip to main content
Gene Therapy Net RSS feed Follow Gene Therapy Net on Twitter LinkedIn - Gene Therapy Net discussion group Facebook - Gene Therapy Net

Newsletter August 2017

News: Gene Therapy Corrects Factor VIII Levels in Hemophilia A
Patients with hemophilia A who received a gene for coagulation factor VIII (FVIII) packaged in a viral vector had sustained levels of FVIII during 1 year of observation, eliminating spontaneous bleeds[2]. Most of them did not need FVIII infusions even in the case of major trauma or surgery. In a late-breaking abstract session here at the International Society on Thrombosis and Hemostasis 2017 Congress, Dr John Pasi (Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK) said six out of the seven patients in one dose cohort have achieved normal factor VIII levels.

News: Commercializing Cell and Gene Therapies
It takes a commitment to innovation, seamless coordination and the support of an experienced partner to overcome every barrier on the journey from clinical to commercial success.
Every moment counts when working with life-saving and industry changing treatments. Our white paper offers actionable insights for those ready to shape this new landscape. Authored by AmerisourceBergen’s multi-disciplinary and market-leading experts, readers will learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.


Company: Cobra Biologics and Pharmaceutical Services
Cobra provides a comprehensive biologics and pharmaceuticals service offering, with multi-functional and experienced project teams nurturing customers’ products from pre-clinical through to clinical and commercial manufacture within three GMP approved facilities. Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. Cobra offers a broad range of integrated and stand-alone contract services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, Cobra take pride in their manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.

- 24 - 25 August 2017, Gene Therapy Bioproduction Conference, Boston, MA
- 31 August - 1 September 2017, 2nd International Conference on Nucleic Acids, Molecular Biology & Biologics Conference, Philadelphia, PA
- 11 - 13 September 2017, Manufacturing Cell and Gene Therapy Products, London,UK
- 19 - 21 September 2017, 3rd Annual Phacilitate Cell & Gene Therapy Europe, Berlin, Germany
- 25 - 28 September 2017, Cell & Gene Therapy Bioprocessing & Commercialization, Boston, MA
- 27 - 28 September 2017, Annual Summit on Cell Therapy and Molecular Medicine, Chicago, Il
- 4 – 6 October 2017, Cell & Gene Meeting on the Mesa, La Jolla, CA
- 17 – 20 October 2017, XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany
- 18 – 19 October 2017, Market Access for Cell and Gene Therapies Congress, London, UK
- 31 October – 2 November 2017, Gene Therapy for Rare Disorders Europe, London, UK
- 9 - 10 November 2017, 3rd Annual Genome Editing Congress, London, UK
- 9 - 10 November 2017, 3rd Annual Cell & Gene Therapy Congress, London, UK
- 13 - 15 November 2017, World Orphan Drug Congress, Barcelona, Spain
- 15 - 17 November 2017, 16th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases, Sonoma, California
- 23 - 25 January 2018, Cell & Gene Therapy World event 2018, Miami, Fl
- 15 March 2018, British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2018, Oxford, UK
- 15 - 17 March 2018, 7th International Conference and Exhibition on Cell and Gene Therapy, London, UK
- 27 April 2018, Annual conference of the British Society for Gene and Cell Therapy (BSGCT), Cardiff, Wales, UK
- 16 - 19 May 2018, American Society of Gene and Cell Therapy (ASGCT) 21th Annual Meeting, Chicago, IL


Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines. Other information websites created and maintained by the owner of Gene Therapy Net are Dengue Virus Net, Influenza Virus Net, Ebola Virus Net, Chikungunya Virus Net and Zika Virus Net.
To unsubscribe from the Newsletter, please login and edit your subscription details, or {unsubscribe}unsubscribe direct{/unsubscribe}, or contact us. You are currently registered as: {subtag:name}, email address: {subtag:email}.

Advertise on this site?